Morgan Stanley Maintains Equal-Weight on Summit Materials, Lowers Price Target to $37
Morgan Stanley analyst Courtney Yakavonis maintains Summit Materials (NYSE:SUM) with a Equal-Weight and lowers the price target from $41 to $37.
Summit Materials: Q1 Earnings Insights
Summit Materials (NYSE:SUM) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Earnings
Summit Materials missed estimated earnings by 7.89%, reporting an EPS of $-0.41 versus an estimate of $-0.38.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Morgan Stanley Maintains Equal-Weight on Summit Materials, Lowers Price Target to $41
Morgan Stanley analyst Courtney Yakavonis maintains Summit Materials (NYSE:SUM) with a Equal-Weight and lowers the price target from $42 to $41.
Summit Materials Q4 Adj. EPS $0.27 Beats $0.26 Estimate, Sales $553.43M Miss $600.48M Estimate
Summit Materials (NYSE:SUM) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.26 by 3.85 percent. This is a 8 percent increase over earnings of $0.25 per share from the same
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
Barclays Maintains Equal-Weight on Summit Materials, Raises Price Target to $40
Barclays analyst Adam Seiden maintains Summit Materials (NYSE:SUM) with a Equal-Weight and raises the price target from $35 to $40.
Morgan Stanley Maintains Equal-Weight on Summit Materials, Raises Price Target to $45
Morgan Stanley analyst Courtney Yakavonis maintains Summit Materials (NYSE:SUM) with a Equal-Weight and raises the price target from $36 to $45.
Where Summit Materials Stands With Analysts
Summit Materials (NYSE:SUM) has observed the following analyst ratings within the last quarter: